Open Access

ARTICLE

dbSCI: A manually curated database of SARS-CoV-2 inhibitors for COVID-19

QIANG WANG^#, GUO ZHAO^#, LONGXIANG XIE^#, XUAN LI, XIXI YU, QIONGSHAN LI, BAOPING ZHENG, ZULIPINUER WUSIMAN, XIANGQIAN GUO^*

Institute of Biomedical Informatics, School of Software, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Academy for Advanced Interdisciplinary Studies, Henan University, Kaifeng, 475004, China

* Corresponding Author: XIANGQIAN GUO. Email:

(This article belongs to the Special Issue: Bioinformatics Study of Diseases)

BIOCELL 2023, 47(2), 367-371. https://doi.org/10.32604/biocell.2023.025310

Received 05 July 2022; Accepted 22 August 2022; Issue published 18 November 2022

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen of the ongoing coronavirus disease 2019 (COVID-19) global pandemic. Here, by centralizing published cell-based experiments, clinical trials, and virtual drug screening data from the NCBI PubMed database, we developed a database of SARS-CoV-2 inhibitors for COVID-19, dbSCI, which includes 234 SARS-CoV-2 inhibitors collected from publications based on cell-based experiments, 81 drugs of COVID-19 in clinical trials and 1305 potential SARS-CoV-2 inhibitors from bioinformatics analyses. dbSCI provides four major functions: (1) search the drug target or its inhibitor for SARS-CoV-2, (2) browse target/inhibitor information collected from cell experiments, clinical trials, and virtual drug screenings, (3) download, and (4) submit data. Each entry in dbSCI contains 18 types of information, including inhibitor/drug name, targeting protein, mechanism of inhibition, experimental technique, experimental sample type, and reference information. In summary, dbSCI provides a relatively comprehensive, credible repository for inhibitors/drugs against SARS-CoV-2 and their potential targeting mechanisms and it will be valuable for further studies to control COVID-19.

---

Keywords

---